BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
PFA re-energizes afib market
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Sunday, September 1, 2024
See today's BioWorld
Home
» Opna Bio recasts mental retardation protein as cancer immunotherapy target
To read the full story,
subscribe
or
sign in
.
Newco news
Opna Bio recasts mental retardation protein as cancer immunotherapy target
Nov. 22, 2022
By
Anette Breindl
No Comments
Swiss-American startup Opna Bio SA launched this week with a $38 million series A, a
Science
paper on one of its targets and a pipeline stretching from preclinical to phase II.
BioWorld
Newco news
Cancer
Series A